The French Tech Journal

Throughout August, we're revisiting eight long-form FTJ articles from the past year whose themes continue to resonate. From AI and deeptech to sovereignty, cybersecurity and global scale, they explore the ideas, companies and debates shaping French Tech.

Throughout August, we're revisiting eight long-form FTJ articles whose themes continue to resonate today. From AI and deeptech to sovereignty, cybersecurity and global scale, they explore the ideas, companies and debates shaping French Tech. We hope you e

Throughout August, we're revisiting eight long-form FTJ articles whose themes continue to resonate today. From AI and deeptech to sovereignty, cybersecurity and global scale, they explore the ideas, companies and debates shaping French Tech. We hope you e

Inside this week's edition: Can physics transform cancer treatment and also generate $6 billion in annual sales? Nanobiotix CEO Laurent Lévy believes so. In an exclusive interview, he explains why the company's physics-based approach could underpin a new

For most biotech companies, the challenge is biological: discovering a new molecule capable of changing the course of disease. Nanobiotix's founders believe that in some cases the answer is physics, not biology.That conviction has shaped the Paris-based c

Inside this week's edition: Cathay Innovation's Denis Barrier explains why Moonshot AI's Kimi K3 is an open-source "Sputnik moment," what it reveals about AI's accelerating economics, and why Europe needs less self-promotion and more relentless focus. Rea

When I caught up with Denis Barrier last week, the Moonshot AI frenzy was entering its umpteenth news cycle, and the co-founder and CEO of Cathay Innovation sounded like a man enjoying being right.The Paris-based firm announced its investment in Moonshot

Data Point: Drysdale Zooms To #3 Dealroom's ranking of the most active investors in French startups during H1 2026 shows Bpifrance and Kima Ventures leading. Of course, of course. But the big surprise is that the recently launched Drysdale Ventures has al

Inside this week's edition: HR Path's near-$1 billion refinancing gives the profitable French HR specialist fresh firepower for global expansion without an IPO or surrendering founder control. CEO François Boulet says he's targeting $1 billion in revenue,

HR Path CEO and Co-Founder François Boulet wants you to know that he's not here for the money. Of course, that may sound easy to say after announcing a refinancing that placed the company's value close to $1 billion and positioned the French company to ma